Cereno Scientific has enrolled 9 additional patients in its Expanded Access Program with CS1 providing more long-term safety and efficacy data in rare disease PAH December 27, 2024
BioStock has published an article and interview with CEO Sten R. Sörensen on the positive topline results from Cereno Scientific’s Phase IIa trial on CS1 in PAH October 3, 2024
Cereno Scientific signs agreement with Fluidda, to evaluate the impact of its HDAC inhibitor CS1 on reverse remodeling of pulmonary vessels in patients with PAH September 30, 2024